No description available.

Successful adoptive immunotherapy (AIT) for cancer relies on the infusion of in vitro expanded, tumor-reactive lymphocytes with a goal of generating productive tumor immunity. Previously, our lab has developed a protocol to activate selectively tumor-reactive T lymphocytes in vitro using two pharmacologic agents, bryostatin-1 and ionomycin. Following the pharmacological stimulation, conventionally, IL-2 is added to stimulate in vitro proliferation. In this report, alternate cytokines from the common cytokine receptor γ-chain family, namely IL-7 and IL-15, were explored as the alternative cytokine supplements. We found that tumor DLN cells activated in vitro with B/I and cultured in IL-7/15 alternate common γ-chain cytokines expanded better than IL-2 cultured cells. Furthermore, immunosuppressive myeloid-derived suppressor cells from the tumor microenvironment were targeted with a chemotherapeutic agent, gemcitabine. Despite combining gemcitabine and the T lymphocytes expanded in IL-7/15, AIT failed to induce regression of large established 4T1 mammary flank tumors.

Currently, in most situations, the autologous immune system is unable to eradicate the residual leukemic burden persisting after chemo-radiotherapy, but a balance can be established between leukemic and immune cells leading to a clinical remission for several months or years. If this balance is broken, a clinical relapse can occur. The high incidence of relapses in human cancers demonstrates the frequent inefficacy of the immune system to control these residual cells. In this context, allogeneic hematopoietic stem cell transplantation (HSCT) has been proven to be the most effective way to reinforce the immune reaction against leukemia, graft-versus-leukemia (GVL) effect and, so, achieve a definitive eradication of the residual disease in a significant proportion of patients. Indeed, the whole concept of HSCT evolved from an organ transplant concept (to replace a defective ill organ with a new healthy one) to the concept of creating an extraordinary immunotherapeutic platform in which the donor immune system contributes to the eradication of the residual leukemic cells. Thus, the past and present issues remain those of finding the best immunomodulatory modalities to achieve a full engraftment, a powerful GVL effect and no or moderate graft-versus-host disease (GVHD). Different ways to reach this goal, such as post transplant cytokine modulation, specific or global cellular depletion of the graft and post transplant global or specific donor immune cell add-backs, are still extensively studied. Nevertheless, the persistent high relapse rate (RR) observed in leukemia patients after HSCT remains the most important cause of death before transplant-related toxicities. Moreover, since only about 40 to 70% (depending on the ethnic context) of patients with high-risk hematological malignancies, eligible for allogeneic HSCT, have a fully HLA-matched sibling or matched unrelated donor (MUD), a great deal of effort has been invested to make the use of an alternative haploidentical sibling donor feasible. The advantage of this procedure is the immediate availability of a donor for almost all patients. The aim of the work described in this thesis has been to implement a strategy to transplant a patient using a HLA haploidentical donor. The strategy is to try to improve DFS that could be applied both in the autologous or allogeneic context: first, by using nonspecific immune manipulation post transplant and then, by developing specific strategies directed against leukemia antigens. Particularly in the allogeneic situation, the aim was to increase the GVL effect without inducing or aggravating the deleterious GVHD. The first part of this thesis described our own clinical results, consisting of three consecutive phase I/II studies, in which we tried to determine the feasibility of giving prophylactic donor lymphocyte infusions (DLI) post transplant and the effect of replacing granulocyte colony-stimulating factor (G-CSF), typically used to speed up neutrophil recovery, with granulocyte macrophage colony-stimulating factor (GM-CSF), which is known for its immunomodulatory properties. The slow immune reconstitution in haploidentical transplant is chiefly responsible for the high incidence of early lethal viral and fungal infections, and most probably for early relapses; therefore, we sought to accelerate and strengthen the post transplant immune reconstitution without increasing the GVHD rate. Thus, we have studied the impact of post transplant growth factor administration and of unselected DLI in haploidentical transplant. We have also implemented, in our center, anti-cytomegalovirus (CMV) specific T cell generation and infusion to improve anti-CMV immune reconstitution. Since then, our results have been pooled in a multi-center analysis performed by the European Bone Marrow Transplantation group (EBMT) allowing us to compare our results with those of the entire group. We have also participated in the design of an ongoing study aimed at selectively depleting the graft from alloreactive T cells, and improving post transplant T cell add-backs. In our attempts to generate and expand ex vivo lymphocytes (directed against pathogens (CMV) and leukemia-associated antigens, Wilms' tumor gene 1 (WT1) and to use them in vivo, we found inconsistent results (in the case of WT1) using classical clinical grade dendritic cells (DC) generated and matured in bags, as was the case for the majority of the teams worldwide. This led us to question the full functionality of these DC and we undertook a thorough comparative analysis of DC generated and differentiated in bags and in plates (typical for most pre-clinical studies). This analysis showed us that one cannot transpose pre-clinical studies (using culture plates) directly to clinical protocols (generally using clinical grade culture bags) and that DC generated in bags are functionally deficient. We learned that, if we want to use a DC vaccine to improve the GVL effect in haploidentical transplant, we will have to be careful about the technique by which they are generated. To improve immunotherapeutic approaches, the understanding of the mechanisms underlying tumor tolerance and how to manipulate them is critical in the development of new effective immunotherapeutic clinical trials. This is why we currently focus on how to obtain effective in vivo anti-leukemia immune reactions using an ex-vivo manipulated product to trigger the immunotherapeutic response. More specifically, we are analyzing the impact of regulatory T cell (Tregs) depletion and function for an adequate anti-leukemic immune response. This pre-clinical work aims at improving the outcome of leukemia patients who have relapsed and been put back into second remission and at decreasing the RR after HSCT, especially in the field of haploidentical transplantation. In conclusion, haploidentical transplantation has become a valuable tool. The results are at least similar to those obtained using MUD when performed in the same group of patients. Specific immunomodulation post transplant can affect events such as GVHD and GVL, but clinically we are still at the level of nonspecific manipulations. It is our hope that ongoing pre-clinical work will enable us to perform specific anti-pathogen and anti-leukemia immune manipulation that will favorably influence the patient outcome. / Dans la majorité des situations, le système immunitaire autologue est incapable d’éradiquer les cellules leucémiques résiduelles qui échappent à la radiothérapie et à la chimiothérapie, cependant un équilibre peut s’établir entre les cellules leucémiques et immunitaires aboutissant à une rémission pouvant durer plusieurs mois ou années. Si cet équilibre se rompt, une rechute clinique peut se déclarer. Dans ce contexte, il est prouvé que la greffe allogénique de cellules souches hématopoïétiques est le moyen le plus efficace de renforcer les réactions immunitaires contre la leucémie par la réaction du greffon contre la leucémie et ainsi d’obtenir une éradication définitive de la maladie résiduelle chez un nombre significatif de patients. En effet, le concept global de l’allogreffe de cellules souches hématopoïétiques a évolué du concept de transplantation d’organe (remplacement d’un organe malade par un nouvel organe sain) vers celui de créer une extraordinaire plateforme d’immunothérapie à travers laquelle le système immunitaire du donneur contribue à l’éradication des cellules leucémiques persistantes. Donc, la problématique reste celle de trouver les meilleures modalités d’immunomodulation pour achever une prise du greffon, un effet anti-leucémique puissant du greffon, et l’absence ou un minimum d’effet du greffon contre l’hôte. Différentes stratégies existent pour atteindre cet objectif, comme l’utilisation de cytokines pour moduler la reconstitution immunitaire, des déplétions cellulaires globales ou spécifiques du greffon et l’infusion de cellules immunes «globales» ou spécifiques du donneur après greffe. Ces stratégies sont encore largement à l’étude. Néanmoins, la persistance d’un taux de rechute élevé observé chez les patients leucémiques, après allogreffe reste la cause principale de décès, avant celle liée à la toxicité de la greffe. De plus, étant donné que seulement environ 40 à 70% (dépendant de l’origine ethnique) des patients avec une hémopathie à haut risque, éligibles pour une greffe allogénique, ont un donneur familial ou non familial complètement HLA compatible, des efforts importants ont été développés pour rendre faisable l’utilisation de donneurs familiaux alternatifs, haploidentiques. L’avantage de cette approche est l’accès immédiat à un donneur pour quasiment tous les patients. Le but du travail décrit dans cette thèse a été l’implémentation d’une stratégie d’allogreffe utilisant un donneur haploidentique. Le travail vise également à développer de façon plus large des stratégies qui peuvent améliorer le taux de survie sans rechute, non seulement dans le contexte des greffes haploidentiques, mais également dans le cadre des greffes allogéniques en général, ainsi que dans les situations autologues : premièrement, par la manipulation immunitaire non spécifique après greffe et ensuite par le développement de stratégies spécifiques dirigées contre des antigènes leucémiques. En particulier dans la situation allogénique, le but a été d’augmenter l’effet du greffon contre la leucémie sans induire ou aggraver l’effet délétère du greffon contre l’hôte. La première partie de la thèse décrit les résultats cliniques de notre propre protocole de greffe haploidentique, qui a consisté en trois études consécutives de phase I/II. Dans ces études, nous avons voulu déterminer la faisabilité de réaliser des infusions prophylactiques de lymphocytes du donneur après transplantation, et l’impact du remplacement du « granulocyte colony-stimulating factor » (G-CSF), largement utilisé pour permettre une récupération en polynucléaires neutrophiles plus rapide, par du « granulocyte-macrophage colony-stimulating factor » (GM-CSF), lequel est connu pour ses propriétés immunomodulatrices différentes. La reconstitution immunitaire très lente après greffe haploidentique est majoritairement responsable de l’incidence élevée de décès par infections virales et fungiques précoces, et très probablement des rechutes précoces. C’est pourquoi nous avons cherché à accélérer et à renforcer la reconstitution immunitaire post-greffe sans augmenter la fréquence de réaction du greffon contre l’hôte. Nous avons donc étudié l’impact de l’administration de facteurs de croissance et l’infusion de lymphocytes non sélectionnés du donneur en post greffe haploidentique. Nous avons également implémenté dans notre centre, la génération et l’infusion de lymphocytes T spécifiques anti-cytomégalovirus (CMV) afin d’améliorer la reconstitution immunitaire anti-CMV. D’autre part, nos résultats ont été regroupés dans une étude multicentrique menée par le groupe européen de transplantation de moelle osseuse (EBMT), ce qui nous a permis de comparer nos résultats avec ceux de l’entièreté du groupe. Nous avons parallèlement participé à la conception d’une étude actuellement en cours ayant pour but d’améliorer la reconstitution immunitaire après greffe par la déplétion sélective du greffon en lymphocytes T alloréactifs et par l’infusion après greffe de lymphocytes T du donneur également sélectivement déplétés en lymphocytes T alloréactifs. Afin d’optimaliser l’effet anti-leucémique du système immunitaire, nous avons débuté un protocole de vaccination par cellules dendritiques (DCs). Ces cellules dendritiques étaient chargées en lysat de blastes leucémiques dans le cas de patients présentant au diagnostic une leucémie aigue surexprimant l’oncogène 1 de la tumeur de Wilms (WT1). Néanmoins dans nos travaux de génération et d’expansion ex-vivo de lymphocytes T spécifiques de l’antigène WT1, utilisant les DCs de grade clinique, générées et maturées en poches, nous avons rencontré des résultats inconsistants, comme c’était le cas dans la majorité des protocoles cliniques internationaux de vaccination. Nous nous sommes alors posé la question de la fonctionnalité globale de ces cellules et nous avons entrepris une analyse comparative poussée des DCs générées et différenciées en poches ou en plaques. Les DCs générées en plaques sont celles utilisées dans la plupart des travaux précliniques. Cette analyse nous a montré que l’on ne pouvait pas directement transposer les résultats précliniques basés sur des DCs générées en plaques dans des protocoles cliniques basés sur des DCs générées en poches, car ces dernières présentent des déficits fonctionnels importants. Nous avons appris que si l’on voulait utiliser un vaccin à base de cellules dendritiques pour améliorer l’effet du greffon contre la leucémie dans les greffes allogéniques, nous devions être très attentifs quant au protocole utilisé pour la génération de ces vaccins cellulaires. Pour améliorer les approches immunothérapeutiques, la connaissance des mécanismes qui établissent la tolérance tumorale et des façons de manipuler ceux-ci, est critique dans le développement de nouveaux protocoles efficaces. C’est pourquoi nous nous concentrons actuellement sur les conditions nécessaires à l’obtention in vivo d’une réaction immune anti-leucémique efficace lors de l’utilisation d’un produit cellulaire manipulé ex vivo. Plus spécifiquement, nous analysons l’impact de la déplétion en lymphocytes T régulateurs (Tregs) sur la réponse anti-leucémique. Ce travail préclinique a pour but d’améliorer le devenir de patients leucémiques qui ont rechutés et ont été mis en seconde rémission, ainsi que de diminuer le taux de rechute après allogreffe, spécifiquement après greffe haploidentique. En conclusion, la transplantation haploidentique est actuellement un outil précieux pour de nombreux patients. Les résultats sont au minimum similaires à ceux qui sont obtenus par les greffes non-familiales HLA identiques lorsqu’elles sont pratiquées dans les mêmes groupes de patients. L’immunomodulation spécifique après greffe peut affecter des événements comme la réaction du greffon contre l’hôte et la réaction du greffon contre la leucémie, mais en pratique clinique nous en sommes encore au niveau de la manipulation aspécifique. Nous espérons que les travaux précliniques actuels vont nous permettre d’appliquer des stratégies spécifiques et d’obtenir une manipulation immune anti-leucémique qui aura une influence favorable significative sur le devenir des patients.

No description available.

Myeloid derived suppressor cells (MDSCs) are heterogeneous population of immature cells at various stages of differentiation, characterized by the presence of CD11b and Gr1 in mice. They are major contributors of the tumor-induced immune suppression against the tumors. So far, various strategies have been introduced to overcome the endogenous MDSCs. Most of these approaches rely on the elimination of MDSCs and it is not clear whether tumor-reactive T cells may be differentiated towards phenotypes that are refractory to MDSCc. Our laboratory has previously shown that high affinity T cells derived from tumor-sensitized wild-type FVB mice and expanded ex vivo with the alternating common gamma chain cytokine formulation (initiation of culture with IL-7 + IL-15 followed by one day pulse with IL-2 and continuation of culture with IL-7 + IL-15) can successfully induce tumor regression in FVBN202 transgenic mouse model of breast carcinoma upon adoptive immunotherapy (AIT), only when combined with the depletion of endogenous MDSCs. In this study we have introduced a novel formulation of the sequential common gamma chain cytokines (initiation of culture with IL-7 + IL-15 followed by the expansion with IL-2 until 6 days) for the ex vivo expansion of the autologous and tumor-sensitized low affinity T cells derived from FVBN202 mice and further used for AIT. This novel formulation induced differentiation of tumor-reactive CD8+ T cells mainly towards effector and effector/memory phenotypes that were refractory to MDSCs in vitro and in vivo. AIT by using these T cells induced rejection of primary neu positive tumors and generated long-term memory responses against the recall tumor challenge. Importantly, these T cells also resulted in the inhibition of neu antigen negative relapsed tumor cells. Our findings in the present study provide a platform for AIT of breast cancer patients. .

Infusões de células T e células NK (Natural Killer) de sangue periférico estão sendo realizadas para tratamento de malignidades. Os linfócitos propagados ex vivo, em normóxia (20% O2), são intravenosamente infundidos e precisam sobreviver a hipóxia associada a circulação venosa, da medula óssea (5% O2) e do microambiente tumoral (1% O2). O objetivo principal deste estudo foi determinar a capacidade proliferativa das células humanas T e NK em normóxia (20% O2) versus hipóxia (1% O2), por 28 dias, utilizando uma célula apresentadora de antígeno artificial (aAPC) para propagação em grau clínico. As células T expostas a hipóxia cresceram 100 vezes menos que as células T cultivadas em normóxia, enquanto que houve uma diminuição de 1000 vezes na taxa proliferativa das células NK hipóxicas, que exibiram um aumento na apoptose bem como um prejuízo na citotoxicidade. Hipóxia também induziu uma diminuição na expressão dos receptores KIR, NCR e NKG2D das células NK. Nesta mesma condição, a produção de IL-2 e IFNγ nas células T estavam diminuídas, sendo que nas células NK esse efeito foi mais acentuado. Hipóxia aumentou a expressão de genes relacionados com apoptose, angiogênese e metabolismo glicolítico, os quais estavam moderadamente aumentados nas células T, mas profundamente super-regulados nas células NK. Os níveis de ATP nas células T foram muito similares em ambas as condições de oxigênio, mas intensamente diminuídos nas células NK cultivadas em hipóxia. Também se observou, que a expressão do miR-210 induzido por hipóxia, estava super regulada nas células NK hipóxicas correlacionando com a perda da expressão da molécula NCAM/CD56. Em conjunto, os resultados deste estudo demonstram um maior impacto da hipóxia sobre as atividades proliferativas e citotóxicas das células NK estimuladas por aAPCs. Estudos adicionais são necessários para o entendimento do impacto deste comportamento das células NK em condições hipóxicas sobre a imunoterapia celular adotiva. / Infusions of T cells and natural killer (NK) cells from peripheral blood (PB) are being undertaken for the treatment of malignancies. Lymphocytes are propagated ex vivo in normoxia (20% O2) and intravenously infused and must survive hypoxia associated with venous blood and bone marrow (5% O2), and the tumor environment (1% O2). The objective this study was to determine the ability of T and NK cells to proliferate under normoxia (20% O2) versus hypoxia (1% O2) over 28 days using an artificial antigen presenting cells (aAPC) to propagate clinical-grade lymphocytes. T cells continuously exposed to 4 weeks of hypoxia grew at a rate of 100-fold less than T cells cultured in normoxia while the proliferative rate of NK cells lagged by 1,000-fold, behind normoxic conditions. Hypoxic cultured NK cells exhibit an increase in apoptosis as well as a correspondent impairment in cytotoxicity. In low oxygen tension the expression of KIR, NCR, and NKG2D receptors were decreased in NK cells. In hypoxia, the production of IL-2 and IFNγ were decreased in T cell and more so in NK cell. Chronic hypoxia increased the expression of related apoptosis, glycolytic metabolism and angiogenesis genes which were moderately increased in T cells but profoundly upregulated in NK cells. ATP levels in T cell were very similar in both oxygen conditions, but profoundly diminished in NK cells under hypoxia. We also noted that hypoxia inducible miR-210 levels are up regulated in hypoxic NK cells correlating with loss of CD56 expression. Taken together, this data show that a greater impact of hypoxia on proliferative and cytotoxic activity of NK cells activated by artificial antigen-presenting cells. More studies are needed to understand the impact of this behavior on the cell adoptive immunotherapy.

Infusões de células T e células NK (Natural Killer) de sangue periférico estão sendo realizadas para tratamento de malignidades. Os linfócitos propagados ex vivo, em normóxia (20% O2), são intravenosamente infundidos e precisam sobreviver a hipóxia associada a circulação venosa, da medula óssea (5% O2) e do microambiente tumoral (1% O2). O objetivo principal deste estudo foi determinar a capacidade proliferativa das células humanas T e NK em normóxia (20% O2) versus hipóxia (1% O2), por 28 dias, utilizando uma célula apresentadora de antígeno artificial (aAPC) para propagação em grau clínico. As células T expostas a hipóxia cresceram 100 vezes menos que as células T cultivadas em normóxia, enquanto que houve uma diminuição de 1000 vezes na taxa proliferativa das células NK hipóxicas, que exibiram um aumento na apoptose bem como um prejuízo na citotoxicidade. Hipóxia também induziu uma diminuição na expressão dos receptores KIR, NCR e NKG2D das células NK. Nesta mesma condição, a produção de IL-2 e IFNγ nas células T estavam diminuídas, sendo que nas células NK esse efeito foi mais acentuado. Hipóxia aumentou a expressão de genes relacionados com apoptose, angiogênese e metabolismo glicolítico, os quais estavam moderadamente aumentados nas células T, mas profundamente super-regulados nas células NK. Os níveis de ATP nas células T foram muito similares em ambas as condições de oxigênio, mas intensamente diminuídos nas células NK cultivadas em hipóxia. Também se observou, que a expressão do miR-210 induzido por hipóxia, estava super regulada nas células NK hipóxicas correlacionando com a perda da expressão da molécula NCAM/CD56. Em conjunto, os resultados deste estudo demonstram um maior impacto da hipóxia sobre as atividades proliferativas e citotóxicas das células NK estimuladas por aAPCs. Estudos adicionais são necessários para o entendimento do impacto deste comportamento das células NK em condições hipóxicas sobre a imunoterapia celular adotiva. / Infusions of T cells and natural killer (NK) cells from peripheral blood (PB) are being undertaken for the treatment of malignancies. Lymphocytes are propagated ex vivo in normoxia (20% O2) and intravenously infused and must survive hypoxia associated with venous blood and bone marrow (5% O2), and the tumor environment (1% O2). The objective this study was to determine the ability of T and NK cells to proliferate under normoxia (20% O2) versus hypoxia (1% O2) over 28 days using an artificial antigen presenting cells (aAPC) to propagate clinical-grade lymphocytes. T cells continuously exposed to 4 weeks of hypoxia grew at a rate of 100-fold less than T cells cultured in normoxia while the proliferative rate of NK cells lagged by 1,000-fold, behind normoxic conditions. Hypoxic cultured NK cells exhibit an increase in apoptosis as well as a correspondent impairment in cytotoxicity. In low oxygen tension the expression of KIR, NCR, and NKG2D receptors were decreased in NK cells. In hypoxia, the production of IL-2 and IFNγ were decreased in T cell and more so in NK cell. Chronic hypoxia increased the expression of related apoptosis, glycolytic metabolism and angiogenesis genes which were moderately increased in T cells but profoundly upregulated in NK cells. ATP levels in T cell were very similar in both oxygen conditions, but profoundly diminished in NK cells under hypoxia. We also noted that hypoxia inducible miR-210 levels are up regulated in hypoxic NK cells correlating with loss of CD56 expression. Taken together, this data show that a greater impact of hypoxia on proliferative and cytotoxic activity of NK cells activated by artificial antigen-presenting cells. More studies are needed to understand the impact of this behavior on the cell adoptive immunotherapy.

Infusões de células T e células NK (Natural Killer) de sangue periférico estão sendo realizadas para tratamento de malignidades. Os linfócitos propagados ex vivo, em normóxia (20% O2), são intravenosamente infundidos e precisam sobreviver a hipóxia associada a circulação venosa, da medula óssea (5% O2) e do microambiente tumoral (1% O2). O objetivo principal deste estudo foi determinar a capacidade proliferativa das células humanas T e NK em normóxia (20% O2) versus hipóxia (1% O2), por 28 dias, utilizando uma célula apresentadora de antígeno artificial (aAPC) para propagação em grau clínico. As células T expostas a hipóxia cresceram 100 vezes menos que as células T cultivadas em normóxia, enquanto que houve uma diminuição de 1000 vezes na taxa proliferativa das células NK hipóxicas, que exibiram um aumento na apoptose bem como um prejuízo na citotoxicidade. Hipóxia também induziu uma diminuição na expressão dos receptores KIR, NCR e NKG2D das células NK. Nesta mesma condição, a produção de IL-2 e IFNγ nas células T estavam diminuídas, sendo que nas células NK esse efeito foi mais acentuado. Hipóxia aumentou a expressão de genes relacionados com apoptose, angiogênese e metabolismo glicolítico, os quais estavam moderadamente aumentados nas células T, mas profundamente super-regulados nas células NK. Os níveis de ATP nas células T foram muito similares em ambas as condições de oxigênio, mas intensamente diminuídos nas células NK cultivadas em hipóxia. Também se observou, que a expressão do miR-210 induzido por hipóxia, estava super regulada nas células NK hipóxicas correlacionando com a perda da expressão da molécula NCAM/CD56. Em conjunto, os resultados deste estudo demonstram um maior impacto da hipóxia sobre as atividades proliferativas e citotóxicas das células NK estimuladas por aAPCs. Estudos adicionais são necessários para o entendimento do impacto deste comportamento das células NK em condições hipóxicas sobre a imunoterapia celular adotiva. / Infusions of T cells and natural killer (NK) cells from peripheral blood (PB) are being undertaken for the treatment of malignancies. Lymphocytes are propagated ex vivo in normoxia (20% O2) and intravenously infused and must survive hypoxia associated with venous blood and bone marrow (5% O2), and the tumor environment (1% O2). The objective this study was to determine the ability of T and NK cells to proliferate under normoxia (20% O2) versus hypoxia (1% O2) over 28 days using an artificial antigen presenting cells (aAPC) to propagate clinical-grade lymphocytes. T cells continuously exposed to 4 weeks of hypoxia grew at a rate of 100-fold less than T cells cultured in normoxia while the proliferative rate of NK cells lagged by 1,000-fold, behind normoxic conditions. Hypoxic cultured NK cells exhibit an increase in apoptosis as well as a correspondent impairment in cytotoxicity. In low oxygen tension the expression of KIR, NCR, and NKG2D receptors were decreased in NK cells. In hypoxia, the production of IL-2 and IFNγ were decreased in T cell and more so in NK cell. Chronic hypoxia increased the expression of related apoptosis, glycolytic metabolism and angiogenesis genes which were moderately increased in T cells but profoundly upregulated in NK cells. ATP levels in T cell were very similar in both oxygen conditions, but profoundly diminished in NK cells under hypoxia. We also noted that hypoxia inducible miR-210 levels are up regulated in hypoxic NK cells correlating with loss of CD56 expression. Taken together, this data show that a greater impact of hypoxia on proliferative and cytotoxic activity of NK cells activated by artificial antigen-presenting cells. More studies are needed to understand the impact of this behavior on the cell adoptive immunotherapy.

Although the physiological consequences of Notch signaling in hematopoiesis have been extensively studied, the differential effects of individual notch cleavage products remain to be elucidated. Given that a disintegrin and metalloproteinase 10 (ADAM10) is a critical regulator of Notch and that its deletion is embryonically lethal, we generated transgenic mice that overexpress ADAM10 at early stages of lymphoid and myeloid development (A10Tg). ADAM10 transgene expression alters hematopoiesis post-hematopoietic Lineage-Sca-1+c-kit+ (LSK) subset differentiation but prior to lineage commitment of progenitor populations. This results in delayed T cell development, abrogated B2 cell development, and dramatic expansion of functionally active myeloid derived suppressor cells (MDSCs) in A10Tg mice. Given ADAM10’s role in Notch signaling, we hypothesized that the observed hematopoietic alterations may be a consequence of perturbed Notch signaling. In fact, blockade of ADAM10 (S2) rescues B cell development and reduces myeloid cells in A10Tg LSKs. Inhibition of γ-secretase (S3) in wild type (WT) LSKs results in enhanced myelopoiesis, mimicking the phenotype of A10Tg mice. Collectively, these findings indicate that the differential cleavage of Notch into S2 and S3 products regulated by ADAM10 is critical for hematopoietic cell-fate determination. Albeit arising in a tumor-free host, A10Tg MDSCs are functionally and phenotypically analogous to tumor-derived MDSCs. A10Tg MDSCs inhibit T cell activation in vitro, and inhibit adoptive immunotherapy (AIT) of metastatic melanoma in vivo, which can be reversed with MDSC depletion. Intriguingly, A10Tg mice are resistant to parasitic infection upon inoculation of Nippostrongylus brasiliensis. However, depletion of MDSCs abrogates this response, while adoptive transfer (AT) of MDSCs into WT mice increases their resistance. This polarized activity of MDSCs is heavily dependent upon interaction with mast cells (MCs). In fact, B16 melanoma cells metastasize more rapidly in WT mice infused with MDSCs when compared to MC-deficient mice (Kit Wsh/Wsh), with or without MDSC AT. Parallel to B16 progression, the ability of MDSCs to promote anti-Nb immunity is significantly diminished in MC-deficient (Kit Wsh/Wsh) mice even with MDSC AT. This augmentation of MDSC activity in the presence of MCs is further corroborated by in vitro co-culture assays that demonstrate a synergistic increase in cytokine production. Furthermore, MDSCs preferentially migrate to the liver in a MC-dependent manner. This interaction is mediated by MC-released histamine. In fact, MDSCs express histamine receptors (HR) and histamine induces MDSC survival, proliferation, and activation. We demonstrate that MDSC activity is abrogated with histamine blockade. Moreover, in humans, allergic patients present with an increase in MDSC population, and MDSCs purified from a stage I breast cancer patient exhibit increased survival in the presence of histamine. Taken together, our studies indicate that MCs and MC-released histamine are critical for the observed functional duality of MDSCs, ranging from immunosuppressive to immunosupportive, depending on the disease state.

<p>This thesis deals with recognition and elimination of tumours by T lymphocytes and their use in adoptive immunotherapy.</p><p>The first tumour-draining lymph node; the sentinel node, is identified by peritumoural injection of a tracer. This is the hypothesised location for the activation of tumour-reactive lymphocytes. Accordingly, proliferation and IFN-γ production in response to autologous tumour extract was detected in sentinel nodes from patients with colon and urinary bladder cancer. Reactivity in metastatic nodes was generally lower or absent, but the non-responsiveness could be subdued in long-term cultures by addition of tumour antigen and IL-2. A novel padlock-probe based method was developed for measuring the T cell receptor Vβ repertoire. Common Vβ gene expansions were detected in tumour-infiltrating lymphocytes and sentinel nodes. Thus, tumour antigens are recognised in sentinel nodes by Th1 lymphocytes, resulting in a clonally expanded cell population that can be further propagated <i>ex vivo</i>.</p><p>Regulatory T cells (Tregs) may contribute to tumour-induced immunosuppression. Immunohistochemical stainings against the pan-T cell marker CD3 and Treg marker FOXP3 was performed on tumour tissue from 20 historical urinary bladder cancer patients. The ratio of FOXP3⁺ to CD3⁺ cells was lower in patients alive 7 years post-cystectomy, suggesting that Tregs in bladder cancer have prognostic implications.</p><p>Lymphocytes were isolated from sentinel nodes from sixteen patients with advanced or high-risk colon cancer. <i>In vitro</i> expansion with addition of autologous tumour extract and IL-2 mainly promoted the outgrowth of CD4⁺ Th1 lymphocytes, which were safely re-transfused to the patients. Four patients responded with complete tumour regression. Survival time in the Dukes’ D patients was significantly increased compared with conventionally treated controls (2.6 versus 0.8 years; p=0.048).</p><p>In conclusion, human solid tumours are recognised in sentinel nodes and <i>in vitro</i> expanded sentinel node-acquired CD4⁺ T lymphocytes seem useful in the treatment of patients with disseminated cancer.</p>